Biocryst Pharmaceuticals Inc Net Income per Employee (BCRX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Biocryst Pharmaceuticals Inc   (NASDAQ: BCRX)
 

Biocryst Pharmaceuticals Inc Net Income per Employee

BCRX's Quarterly Results, Trends, Rankings, Statistics
Biocryst Pharmaceuticals Inc recorded a cumulative net loss of $-385 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 82 other companies achieving higher income per employee. While Biocryst Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 376 to 3751.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BCRX Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change 1441.69 % - - - -
Net Income per Employee (TTM) $ -884,306 -1,052,834 606,577 -20,182 -82,094
BCRX's Total Ranking # 3751 # 376 # 2722 # 3074 # 3243
Seq. Net Income Change - - 1805.92 % 153.67 % 15790.63 %

BCRX Company Profile >> Back to BCRX Efficiency Comparisons >> Compare BCRX Net Income per Employee to its Competitors

BCRX Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 83
Healthcare Sector # 611
Overall Market # 3751

Net Income per Employee Statistics
High Average Low
$ 606,577 $ -252,549 $ -1,052,834
(Dec 31 2025)   (Mar 31 2026)




  News about Biocryst Pharmaceuticals Inc Income per employee

BioCryst Pharmaceuticals Faces Financial Challenges Amidst Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals Grants Stock Options and RSUs to New Employees, Faces Financial Challenges
BioCryst Pharmaceuticals, Inc. recently announced that the compensation committee granted stock options and restricted stock units to new employees as inducements to join the company. However, despite this positive news, the company recorded a significant net loss in the first quarter of 2024. Additionally, compared to other companies in the Biotechnology and Pharmaceuticals industry, BioCryst s overall ranking has deteriorated.
These developments raise questions about the company s financial health and future prospects. It will be crucial for BioCryst to address its financial challenges and improve its performance to remain competitive in the industry.

BioCryst Pharmaceuticals Faces Financial Challenges Amidst Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals Grants Stock Options and RSUs as Inducements to New Employees, Faces Challenges Amidst Cumulative Net Loss
In a recent announcement, BioCryst Pharmaceuticals, Inc. revealed that the compensation committee of its board of directors granted 10 newly-hired employees stock options and restricted stock units (RSUs) as inducements to join the company. The options and RSUs, totaling 79,575 shares and 42,400 shares respectively, were granted on April 30, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
This move comes at a time when BioCryst Pharmaceuticals Inc. has reported a cumulative net loss of $227 million during the twelve months ending in the fourth quarter of 2023. While the inducement grants may be seen as a strategic maneuver to attract top talent and drive company growth, the significant financial loss raises concerns about the company s financial health and future prospects.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-09T22:24:46+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.